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Abstract: Post-translational protein regulation allows for fine-tuning of cellular functions and 
involves a wide range of modifications, including ubiquitin and ubiquitin-like modifiers (Ubls). The 
dynamic balance of Ubl conjugation and removal shapes the fates of target substrates, in turn 
modulating various cellular processes. The mechanistic aspects of Ubl pathways and their biological 
roles have been largely established in yeast, plants, and mammalian cells. However, these modifiers 
may be utilised differently in highly specialised and divergent organisms, such as parasitic 
protozoa. In this review, we explore how these parasites employ Ubls, in particular SUMO, NEDD8, 
ATG8, ATG12, URM1, and UFM1, to regulate their unconventional cellular physiology. We discuss 
emerging data that provide evidence of Ubl-mediated regulation of unique parasite-specific 
processes, as well as the distinctive features of Ubl pathways in parasitic protozoa. We also highlight 
the potential to leverage these essential regulators and their cognate enzymatic machinery for 
development of therapeutics to protect against the diseases caused by protozoan parasites. 
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1. Introduction: When Parasitic Protozoa Met Ubls 
Parasitic protozoa are a diverse polyphyletic group of unicellular eukaryotes that have adapted 
to live in the cells, tissues, or organs of host organisms [1]. These parasites cause diseases of medical 
and veterinary importance and impose a significant socioeconomic burden worldwide (Figure 1). 
Five species of Plasmodium genus are the etiological agents of malaria, a devastating disease that 
affects over 200 million people and claims the lives of over 400 thousand people annually [2]. Human 
African trypanosomiasis, Chagas disease, and leishmaniasis, caused by Trypanosoma brucei, 
Trypanosoma cruzi, and Leishmania spp., respectively, are classed as neglected tropical diseases and 
lead to considerable morbidity and mortality in developing countries [3–5]. A common parasitic 
zoonosis is associated with Toxoplasma gondii, a protozoan parasite that is capable of infecting warm-
blooded animals and humans and may cause congenital disease, abortion, or severe complications in 
immunocompromised individuals [6]. Enteric protozoans Cryptosporidium spp., Giardia lamblia, and 
Entamoeba histolytica cause diarrhoeal illnesses in humans, as well as companion and farm animals. 
While mainly manifesting as self-limiting diarrhoea, these infections may become disabling or fatal 
for very young or immunocompromised individuals and lead to severe complications, such as 
amoebic brain abscesses and necrotising colitis in E. histolytica-infected patients [7]. Trichomoniasis, 
one of the most common sexually transmitted diseases, is caused by Trichomonas vaginalis, a 
protozoan parasite that remains understudied despite being globally widespread and linked to 
adverse pregnancy outcomes and increased HIV susceptibility [8]. Naegleria fowleri, the causative 
agent of a rare, but highly lethal, primary amoebic meningoencephalitis (PAM) with a mortality rate 
estimated at 95–97%, may be considered an emerging pathogen as there are indications of an upward 
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trend in the number of PAM cases over the last two decades and an increasing favourability of 
environmental conditions for the growth of this parasite [9]. Lack of vaccines, limited chemotherapy 
options, and the emergence of drug-resistant parasites are the challenges posed by the majority of 
protozoan diseases. There is a clear clinical need for the development of novel drugs targeting 
parasitic protozoa in order to prevent and treat these diseases [10,11]. 
 
Figure 1. Parasitic protozoa of medical and veterinary importance. 
Many protozoan parasites have intricate life cycles involving progression through multiple 
morphologically and physiologically distinct stages, which requires complex regulation of their gene 
expression. Notably, kinetoplastid parasites, such as Leishmania and Trypanosoma, lack regulatory 
transcription factors and rely predominantly on polycistronic transcription, resulting in a severely 
limited ability to exert transcriptional regulation [12,13]. Furthermore, in Plasmodium, a considerable 
discrepancy between the abundance of mRNAs and corresponding proteins has been demonstrated, 
with the protein abundance peaking on average 11 hours after the peak of the corresponding 
transcript [14]. These observations indicate that the regulation of gene expression in protozoan 
parasites does not solely rely on transcriptional control mechanisms. Instead, the dynamics of 
translation, protein degradation, and post-translational modifications (PTMs) are likely to be key 
regulators of protein expression at the relevant life cycle stages. A wide range of PTMs have been 
reported in protozoans, including phosphorylation, acetylation, succinylation, palmitoylation, 
crotonylation, malonylation, methylation, glycosylation, ubiquitination, and ubiquitin-like (Ubl) 
modifications [15–17].  
‘Ubl’ is a term that encompasses protein modifiers which are structurally and evolutionarily 
related to ubiquitin. The Ubl family includes neural precursor cell-expressed developmentally 
downregulated 8 (NEDD8), small ubiquitin-related modifier (SUMO), ubiquitin-fold modifier 1 
(UFM1), ubiquitin-related modifier 1 (URM1), autophagy-related proteins 8 and 12 (ATG8 and 
ATG12), interferon-stimulated gene 15 (ISG15), and human leukocyte antigen-F adjacent transcript 
10 (FAT10) [18]. A rich variety of Ubls have been found in parasitic protozoa [19–22], with the 
exception of ISG15 and FAT10 (Table 1). These two modifiers have been implicated in immune and 
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stress responses in the context of multicellular organisms [23,24], which may explain their absence in 
unicellular parasitic protozoans. 
Table 1. The range of Ubls identified in different protozoan parasites. The presence or absence of each 
Ubl is denoted by ‘+’ or ‘−‘, respectively. 
 SUMO NEDD8 ATG8 ATG12 URM1 UFM1 ISG15 FAT10 
Plasmodium + + + + + − − − 
Toxoplasma + + + + + + − − 
Trypanosoma + + + + + + − − 
Leishmania + + + + + + − − 
Giardia + + − − + + − − 
Entamoeba + + + − + − − − 
Ubls share certain notable features with ubiquitin, namely the characteristic five-stranded β-
grasp fold [25] and requirement for a mechanistically conserved enzymatic cascade to mediate their 
attachment to substrates. Ubiquitin and the majority of Ubls are covalently attached to their targets, 
mainly lysine residues of protein substrates, via a three-step process sequentially catalysed by the 
modifier-specific E1 activating, E2 conjugating, and E3 ligase enzymes. The formation of polymeric 
chains, resulting from additional moieties being conjugated onto the internal acceptor sites of the 
modifier itself, has been described for ubiquitin and some Ubls, such as SUMO, NEDD8, and UFM1 
[26]. The dynamic nature of ubiquitin and Ubl modifications is underpinned by the existence of 
deubiquitinases (DUBs) and Ubl-specific proteases (Ulps) that can remove the respective 
modifications from their substrates. Additionally, some DUBs and Ulps are responsible for cleaving 
the C-termini of ubiquitin and Ubl precursors to release mature forms of these modifiers, containing 
a C-terminal glycine (Gly) or diglycine (Gly-Gly) motif that is required for activation and conjugation 
to substrates [27]. The translation of URM1, ATG12, and FAT10 mRNAs produces mature forms that 
do not undergo proteolytic processing [26].  
Ubl modifications allow the fine-tuning of their targets by altering their stability, conformation, 
intracellular compartmentalisation, or affinity to binding partners. Consequently, by changing the 
features of their substrates, Ubls regulate numerous cellular processes, including cell cycle 
progression, transcription, stress responses, DNA damage repair, cell signalling, nuclear transport, 
and autophagy [18,28]. 
While robust mass spectrometry-based proteomic techniques have been devised to detect and 
quantify certain PTMs, such as phosphorylation, other types of modifications, notably Ubls, remain 
a challenge to measure directly [29,30]. There has been great progress in developing methods for 
global analysis of ubiquitinated proteins [30], and multiple ubiquitome datasets were released for 
various organisms, including parasitic protozoa [31,32]. However, detection of endogenous Ubl-
modified targets is a more complicated task due to the low abundance and transient nature of these 
modifications. This issue can be mitigated by using sophisticated sample enrichment and processing 
methods, many of which rely on the availability of highly specific reagents (e.g., monoclonal SUMO 
antibodies) [33]. Additionally, the shared Gly-Gly C-terminal remnant produced upon trypsin 
digestion of modified substrates in the course of sample preparation for mass spectrometry of 
NEDD8 and ISG15-modified proteins, as well as ubiquitin-modified ones, further stunts 
investigations. The Gly-Gly signature is a useful feature for the detection of modified peptides in 
mass spectrometry and is widely used for assigning ubiquitination sites [29,30]. As a result, NEDD8 
and ISG15 modifications may be overlooked, obscured by more abundant ubiquitin ones, and require 
complex interventions to ascertain, such as the use of modified NEDD8 enzymatic machinery [34] 
and NEDDylation inhibitors [35]. 
Where experimental data are lacking, the predictive power of bioinformatics can be harnessed 
to guide experimental research. A variety of models for predicting PTM sites on protein substrates 
have been developed [36], some of which were applicable to parasitic protozoa. In particular, 
algorithms based on amino acid sequence motifs [36,37], protein secondary structure [38,39], or a 
combination of both [40], have been devised to determine SUMOylation sites. Enabled by the release 
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of protozoan proteomic and genomic datasets over the last two decades [41–43], computational 
approaches have been instrumental in identifying putative Ubls and enzymes mediating Ubl 
cascades in these organisms based on sequence and structural similarity to relevant conserved 
domains [19–22]. However, due to significant divergence from model organisms and a high 
proportion of proteins without any known homology, functional studies are critical to elucidating 
these pathways in parasitic protozoa. 
Research into the functional aspects of ubiquitin and Ubl pathways has been accelerated by the 
development of activity-based probes [44–46] and inhibitors [47–50] that target modifier-specific 
enzymatic machinery with high specificity. These chemical tools, often coupled with mass 
spectrometry and X-ray crystallography, enable the capture, identification, and structural and 
functional characterisation of enzymes mediating the Ubl cascades. A number of functional studies 
have successfully used activity-based probes and inhibitors to investigate Ubl pathways in parasitic 
protozoa [51–55]. 
Many experimental and computational techniques developed in model organisms are difficult 
to implement in parasitic protozoa due to striking deviations in their genomes, cellular processes, 
and regulatory mechanisms. Another obstacle is the complexity of life cycles and environmental 
requirements of protozoan parasites, making many unsuitable for large-scale cultivation and 
recapitulation of the complete life cycle in the laboratory. This translates into substantial difficulties 
in generating sufficient amounts of parasite material for standard workflows. Although protozoan 
parasites present significant challenges as experimental objects, recently developed genetic 
approaches, such as CRISPR/Cas genome editing [56] and high-throughput transposon insertional 
mutagenesis [57], have expanded the possibilities to conduct functional studies in these organisms.  
Although the body of research addressing the complexity of Ubl functions and pathways is 
steadily growing, it is important to point out that most of the studies are performed using mammalian 
cells or yeast. Such studies are very powerful in elucidating the details of conserved eukaryotic 
processes, but may not fully apply to highly divergent and specialised organisms, parasitic protozoa 
being a prime example. Although underexplored in parasitic protozoa, emerging data indicate that 
Ubls are involved in novel parasite-specific roles, in addition to fulfilling the conserved “core” 
functions. Since the ubiquitin pathway in protozoans has been reviewed earlier [58], here we will 
focus on investigations addressing the more conventional as well as the unexpected functions of Ubls 
in parasitic protozoa. We will also highlight the distinguishing features of Ubl enzymatic machinery 
in these unusual organisms and the potential for Ubl pathways to be targeted by current and novel 
drugs against the diseases caused by parasitic protozoa. 
2. SUMO: Wrestling with Stress and More 
SUMO is one of the most comprehensively studied Ubls that has been found in all eukaryotes 
to date. Unicellular eukaryotes, such as yeast and protozoa, possess a single SUMO-encoding gene, 
while vertebrates and higher plants have multiple SUMO paralogs. Attachment of SUMO to lysine 
residues of protein substrates (SUMOylation) is mediated by the heterodimeric SUMO-activating E1 
enzyme that consists of the Uba2 catalytic subunit (i.e., SAE2) and the Aos1 subunit (i.e., SAE1), the 
SUMO-conjugating E2 enzyme Ubc9, and several SUMO E3 ligases. SUMOylation can occur in an 
E3-independent manner, provided the Ubc9 concentration is high and the substrate contains a 
consensus motif ψKxD/E (ψ—a large hydrophobic amino acid; x—any amino acid). Removal of 
SUMO from modified substrates (deSUMOylation) and maturation of SUMO precursors are 
mediated by SUMO-specific Ulps, most belonging to sentrin-specific protease (SENP) and permuted 
papain fold peptidases of dsRNA viruses and eukaryotes (PPPDE) families [59,60].  
A wide range of proteins have been identified as targets of SUMOylation, linking this PTM to 
the majority of essential processes in eukaryotic cells. The regulatory role of SUMO has been most 
extensively studied in nuclear functions, namely transcription, DNA damage repair, chromatin 
organisation, nuclear transport, and mitosis [60]. It is also becoming evident that there are complex 
relationships between SUMOylation and other PTMs, in particular phosphorylation, acetylation, and 
ubiquitination, which expands the scope of SUMO-mediated regulation [59,60]. In many organisms, 
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changes in SUMOylation have been observed in response to oxidative, osmotic, hypoxic, heat, and 
genotoxic stresses, indicating that SUMO might play a protective role in various types of cellular 
stress [61].  
Considerable variation in protein SUMOylation levels in different P. falciparum intraerythrocytic 
stages has been demonstrated. The peak in the amount of high molecular weight P. falciparum SUMO 
(PfSUMO) conjugates coincides with the trophozoite stage of the intraerythrocytic development cycle 
[62]. During this stage, malaria parasites consume large quantities of host haemoglobin and are 
subject to oxidative stress induced by haemoglobin digestion by-products. Furthermore, PfSUMO 
conjugation can be increased in a dose-dependent manner upon treatment of parasites with 
artemisinin, an antimalarial drug that triggers oxidative stress [63]. Therefore, similar to this Ubl in 
stress responses of other organisms [61], it is likely that increased SUMOylation is a protective 
response against oxidative stress in P. falciparum trophozoites. Notably, downregulation of PfSUMO 
was reported in P. falciparum trophozoites treated with an isocryptolepine derivative ICL-M [64], and 
may interfere with their ability to mount an efficient stress response, thereby contributing to the lethal 
effect of the drug. 
Indications of a parasite-specific role for SUMO were demonstrated by a proteomic study where 
23 proteins emerged as putative PfSUMO substrates in P. falciparum [65]. While many matched 
orthologs of proteins known to be SUMOylated in other organisms, a few comprised novel, parasite-
specific targets. Of particular interest is PfSir2, a nuclear protein involved in transcriptional regulation 
of var genes that confer antigenic variation, implicating SUMOylation in immune evasion. 
Immunofluorescence staining using a monoclonal antibody against PfSUMO revealed the presence 
of this Ubl within parasite nuclei and cytoplasm [62]. Interestingly, a separate study using polyclonal 
antibodies also localised PfSUMO within Maurer’s clefts [65]. These parasite-derived structures are 
disc-shaped cisterns bound by a single membrane that function as sorting and trafficking hubs for 
parasitic proteins destined for export into host red blood cells, in particular onto the red blood cell 
surface, as seen with the var gene product, PfEMP1 [66]. It is possible that SUMOylated proteins of 
parasitic origin are trafficked into erythrocytes. Alternatively, PfSUMO may play a regulatory role in 
the formation and maintenance of Maurer’s clefts or protein sorting and transport in these structures 
[65].  
In silico identification of genes encoding SUMO and the enzymatic machinery required for 
attachment and removal of this Ubl in P. falciparum [19,20,62,65] prompted further research into 
structural and functional aspects of the SUMO pathway in malaria parasites. In vitro studies of 
PfSUMO conjugation pathway demonstrated that PfSUMO E1 (heterodimer PfAos1-PfUba2) and 
PfSUMO E2 (PfUbc9) are catalytically active and can mediate SUMOylation of mammalian RanGAP1, 
a well-characterised SUMO substrate bearing the ψKxD/E consensus motif. PfSUMO E1 is able to 
activate both the P. falciparum SUMO and the human SUMO-2, and RanGAP1 can be modified with 
either of them [62,63]. Although the functional interchangeability underscores the evolutionary 
conservation of this Ubl, the interactions between SUMO E1 and SUMO E2 are organism-specific and 
determined by divergent E1–E2 binding interfaces in P. falciparum enzymes and their human 
counterparts [62,63]. The presence of multiple amino acid residues on PfUba2 and PfUbc9 that dictate 
the selectivity of their interaction indicates potential for development of parasite-specific inhibitors 
targeting this pathway [62,63]. Furthermore, mutations in both PfUba2 and the PfSUMO E3 ligase 
PIAS arose during selection for resistance to high concentrations of the benzoxaborole drug AN13762, 
underscoring the pertinence of the entire SUMO pathway to the mode of action of this drug and 
potentially to other antimalarials [67]. Considering that PfSUMO and the associated enzymatic 
machinery are essential for survival of P. falciparum [57], selective disruption of the key steps in the 
attachment of this Ubl to substrates is likely to be lethal to malaria parasites.  
In terms of SUMO removal from target proteins, bioinformatics analyses predict two P. 
falciparum SUMO-specific Ulps, PfSENP1 (functionally characterised) and PfSENP2 (uncharacterised) 
[55]. It was demonstrated that PfSENP1 removes SUMO moieties from modified RanGAP1 and 
processes SUMO precursors in vitro [55]. Upregulation of this Ulp was observed during the parasite’s 
intrahepatic stage following disruption by γ-irradiation of P. falciparum sporozoites, further 
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supporting a role of SUMOylation in stress response [68]. Highlighting this enzyme’s potential as a 
drug target, the substrate sequence specificity of PfSENP1 was shown to differ significantly enough 
from that of human SENPs, that a class of aza-epoxide small molecule inhibitors were able to 
specifically block replication of P. falciparum in erythrocytes, with parasite clearance and potency of 
PfSENP1 inhibition showing a direct correlation [55]. Although PfSENP2 has not been tested in vitro, 
the H423Y variant of this enzyme was identified by retrospective longitudinal genome surveillance 
as a candidate background mutation contributing to the spread of Kelch13-mediated artemisinin 
resistance in P. falciparum [69]. Assuming PfSENP2 is confirmed as a deSUMOylase, this finding 
suggests that the SUMO pathway is involved in boosting the fitness of artemisinin-resistant parasite 
strains. Moreover, PfSENP2 has a potential to serve as a molecular marker for drug resistance 
surveillance, facilitating the efforts to trace and mitigate the spread of artemisinin resistance in P. 
falciparum populations [69]. 
A comprehensive study of a SENP family protease of T. gondii, TgUlp1, revealed that this 
enzyme is catalytically active, and its expression is intricately regulated by two non-coding RNAs: 
Tg-miR-60 and TgUlp1-NAT1 [70]. Tg-miR-60, the most abundant microRNA (miRNA) species in T. 
gondii, negatively regulates TgUlp1 expression and is the first T. gondii miRNA to be assigned a target. 
TgUlp1-NAT1 is a polyadenylated antisense RNA that is also likely to act as a negative regulator of 
TgUlp1 expression [70]. The existence of such sophisticated mechanisms to modulate the expression 
of TgUlp1 suggests that T. gondii SUMOylation is a highly complex process with multiple layers of 
regulation and clearly deserves further investigation.   
While only 23 proteins emerged as putative PfSUMO substrates in P. falciparum [65], a similar 
approach identified 120 candidate substrates in T. gondii, many of which were consistent with 
SUMOylated orthologs in other organisms [71]. The timing of SUMOylation in T. gondii is tightly 
controlled and responsive to specific cues, exemplified by the transient and considerable increase in 
TgSUMO conjugates at the parasite surface during host cell invasion [71]. Furthermore, T. gondii 
subjected to pH stress to induce in vitro conversion from replicative tachyzoite to latent (cyst) 
bradyzoite stage accumulated TgSUMO conjugates at the bradyzoite parasitophorous vacuole 
membrane (PVM). Additionally, SUMOylation was observed at the wall of tissue cysts formed by T. 
gondii bradyzoites in the murine brain. These findings suggest that SUMO may play a regulatory role 
in T. gondii stress responses, transition between developmental stages, and cyst formation [71]. It was 
demonstrated that monensin, an ionophore drug commonly used to treat coccidiosis and effective 
against T. gondii, downregulates TgSUMO [72]. Decreased TgSUMO levels in monensin-treated T. 
gondii may compromise the ability of the parasites to counteract stress, in particular oxidative stress, 
which is reportedly induced by this drug [73]. 
SUMO has been actively investigated in flagellate protozoans, particularly T. brucei and T. cruzi. 
For both species, SUMO and SUMO-specific enzymatic machinery were bioinformatically predicted 
[74–77] and functionally validated using reconstituted systems in vitro or in bacteria [76,78,79]. 
Conservation of key structural features typical of SUMO orthologs from model organisms was shown 
for T. brucei SUMO by means of NMR spectroscopy [80]. Remarkably, the formation of polymeric 
chains has been reported for SUMO found in T. brucei [78,81] and T. cruzi [79], in contrast to 
apicomplexan parasites that possess SUMO devoid of internal SUMOylation motifs and likely 
lacking a basis for polymeric chain assembly [20]. Although the ability to form poly-TbSUMO chains 
was shown not to be essential for survival of T. brucei in culture, it was implicated in telomere 
positioning, possibly through modulation of protein interaction platforms that are involved in 
chromatin organisation [81]. 
An early mass spectrometry analysis revealed 236 proteins as potential SUMOylation substrates 
in T. cruzi [77]; however, upon applying an improved workflow to the experimental dataset, the 
number of predicted substrates was reduced to only seven [82]. This dramatic difference in number 
of predicted substrates exemplifies how application of different analytical methods can change 
outcomes drastically and underscores the need for further experimental validation of mass 
spectrometry data. In T. brucei, 45 proteins with a total of 53 mapped SUMO acceptor sites were 
unambiguously identified [83]. Proteins associated with nuclear processes accounted for a high 
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proportion of detected substrates, suggestive of a crucial regulatory function in the nucleus of T. 
brucei. 
Indeed, a central role in cell cycle control has been demonstrated across the T. brucei life cycle. 
Silencing of TbSUMO in the proliferative procyclic form (within the midgut of the invertebrate host, 
the tsetse fly) results in growth inhibition, mitotic arrest at the G2/M phase, and failure to properly 
segregate the chromosomes, although cytokinesis does still proceed [74]. Additionally, the Aurora-
like kinase essential for mitotic spindle assembly, chromosome segregation, and cytokinesis in T. 
brucei, TbAUK1, required SUMOylation to properly function in procyclic parasites [84]. Knockdown 
of TbSUMO in the bloodstream form (within the vertebrate host) resulted in growth cessation and 
accumulation of multinucleated cells, indicative of nuclear division in the absence of cytokinesis [85]. 
Notably, while faithful chromosome segregation in numerous other organisms is dependent on 
SUMOylation of DNA topoisomerase-II [86,87], the T. brucei ortholog of this enzyme showed no 
evidence of being regulated by TbSUMO. The centromere-localised cleavage activity of T. brucei 
topoisomerase-II that remains intact in the bloodstream form of the parasite depleted of TbSUMO 
[85] may explain why nuclear division still proceeds in these mutants. Taken together, these data 
suggest different substrates and functions for SUMO throughout the life cycle of T. brucei. 
SUMO has also been implicated in antigenic variation of the T. brucei bloodstream form through 
its regulatory role in Variant Surface Glycoprotein (VSG) expression [88]. T. brucei antigenic variation 
relies on the presence of more than a thousand VSG genes that display mutually exclusive expression 
and continuously switch to evade host immune responses [89]. It was demonstrated that a high level 
of chromatin SUMOylation was associated with the single transcriptionally active VSG expression 
site (VSG-ES) in the T. brucei nucleus [88]. In contrast, SUMO modification of transcriptional factors 
and chromatin is more commonly linked to gene repression in other organisms. The enrichment of 
TbSUMO conjugates in the T. brucei nucleus was unique to the active VSG-ES and involved the 
chromatin regions upstream of the VSG-ES promoter. TbSIZ1/PIAS1 was identified as the SUMO E3 
ligase that mediates the conjugation of TbSUMO onto the chromatin of VSG-ES, which leads to its 
transcriptional activation via RNA polymerase I recruitment. Notably, TbSIZ1-dependent 
SUMOylation of TbRPA1, the largest subunit of RNA polymerase I, was detected [88], and TbSIZ1 
itself appears on the list of reported SUMO substrates [83]. Furthermore, it was demonstrated that 
TbSUMO-modified nuclear protein SNF2PH is recruited to the active VSG-ES promoter to maintain 
RNA polymerase I, and thus, acts as a transcriptional activator to ensure monoallelic expression of 
VSG [90]. Taken together, these observations suggest that transcriptional activation of T. brucei VSG 
is potentially underpinned by multiple different mechanisms of SUMO-mediated regulation. 
Considering the limited capacity of trypanosomes to regulate gene expression at the level of 
transcription, the unusual approach to transcriptional activation of VSG highlights the surprising 
versatility of these biologically unique eukaryotes. SUMO does appear to fulfil more conventional 
functions within trypanosomes as well, seeing as hydrogen peroxide-induced oxidative stress in T. 
brucei triggered increased SUMOylation, suggestive of a role in managing stress-induced damage 
[75]. 
Although SUMO was predominantly enriched in the nucleus of T. cruzi [77,79] and T. brucei 
[74,88], TcSUMO was also observed to localise to the flagellum, and the pattern of its localisation was 
dependent on the developmental stage of T. cruzi [79]. PFR1, a major protein component of the 
paraflagellar rod, a lattice-like structure running alongside the axoneme [91], was confirmed as a 
SUMOylation substrate in T. cruzi, which points to the involvement of TcSUMO in flagellar 
homeostasis and motility [79].  
The presence of genes encoding SUMO and SUMO-specific enzymatic machinery [21,92], as well 
as cytoplasmic and nuclear localisation of this Ubl, have been reported for another flagellate 
protozoan, G. lamblia, in the motile trophozoite form [92]. Knockdown of GlSUMO led to alteration 
of trophozoite cell morphology and distortion of the ventral adhesive disk, a unique and essential 
structure that enables attachment of the parasite to the intestinal mucosa of the host. Furthermore, 
GlSUMO-deficient G. lamblia trophozoites displayed decreased proliferative ability and cell cycle 
arrest at G1/S phase, which resembles the effects of SUMO knockdown in trypanosomes [93]. It was 
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also reported that GlSUMO regulates the ability of G. lamblia trophozoites to transform into dormant 
cysts through modification of the parasite’s substrate arginine deiminase (ADI) [94]. SUMOylation of 
ADI on Lys101 promotes its localisation to the nucleus and leads to downregulation of cyst wall 
proteins (CWPs) expression, a necessary step for allowing the encystation process to complete. A 
potential mechanism of ADI-mediated CWP repression is the deimination of histones at the 
promoters of cwp genes, an epigenetic modification that may be conferred through the catalytic 
activity of ADI in the nucleus [94,95]. Although only 28 proteins were identified as potential 
substrates by means of mass spectrometry [93], the functional evidence discussed above suggests that 
GlSUMO is instrumental in many diverse and essential processes to G. lamblia development, 
including cell cycle progression, cell shape control, adhesive disk formation, and encystation. 
3. NEDD8: Still a Mystery 
NEDD8 is the Ubl evolutionarily most closely related to ubiquitin and has largely been studied 
in the context of its major substrates, Cullins, the scaffold components of the ubiquitin E3 ligase 
family Cullin-RING E3 ligases (CRLs). Counting over 200 members in mammalian cells, CRLs 
represent the largest group of RING E3 ligases and control approximately 20% of cellular 
ubiquitination. Through activation of CRL activity, NEDD8 regulates a wide range of essential 
processes mediated by CRL substrates, including cell cycle progression, growth and differentiation, 
stress responses, DNA repair, and cell signalling [96,97]. Although a number of non-Cullin substrates 
have been reported, such as some E3 ubiquitin ligases, transcription factors, and ribosomal proteins, 
not all of them are backed by strong experimental evidence due to their use of NEDD8 overexpression 
[98,99]. The presence of excess NEDD8 can trigger its activation by the ubiquitin E1 enzyme Uba1 
and results in erroneous attachment to ubiquitin substrates [98,99]. As such, some of the previously 
identified non-Cullin substrates require further validation. 
NEDD8 is attached to lysine residues of protein substrates through the sequential activity of the 
heterodimeric NEDD8-activating E1 (NAE) enzyme, composed of the Uba3 catalytic subunit and the 
Ula1 (also known as NAE1, APPBP1) regulatory subunit, one of two NEDD8-conjugating E2 enzymes 
(Ubc12/Ube2M or Ube2F), and one of several NEDD8 E3 ligases [98,100]. NEDD8-specific Ulp 
(deNEDDylase) activity has been demonstrated for two enzymes: NEDP1 (also known as DEN1, 
SENP8) and COP9 signalosome (CSN). Additionally, a number of DUBs, namely UCHL1, UCHL3, 
Ataxin 3, and USP21, were reported to cleave NEDD8 [100]. CSN and NEDP1 were proven to be of 
key functional significance: the former removes NEDD8 from Cullins, while the latter is instrumental 
in NEDD8 maturation and deNEDDylation of non-Cullin substrates [100]. Despite NEDDylation 
being an essential process in all eukaryotic organisms (with the exception of Saccharomyces cerevisiae 
[100]), this pathway has not been widely studied in parasitic protozoa thus far. 
A notable exception is a study by Liao et al. that functionally characterised NEDD8 in T. brucei 
[101]. The authors demonstrated that although TbNEDD8 can be found throughout the cytosol, it is 
particularly enriched in the nucleus and flagellum. The significance of this Ubl for nuclear and 
flagellar processes was further underscored by the appearance of abnormal flagella and mitotic 
defects in T. brucei depleted of TbNEDD8 [101]. Parasites lacking TbNEDD8 displayed flagellar 
detachment, linking this Ubl to the assembly of the FAZ filament, a cytoskeletal structure that 
connects the flagellum to the cell body. While disrupted spindle formation and chromosomal 
segregation are unexpected effects of TbNEDD8 silencing, aberrant re-replication of DNA in mitotic 
and post-mitotic cells suggests that this Ubl regulates cell cycle progression in T. brucei, akin to the 
role of NEDD8 orthologs in other organisms. NEDDylation was shown to be essential for T. brucei 
survival, and TbNEDD8 knockdown led to a substantial reduction in global protein ubiquitination, 
highlighting the regulatory role of NEDD8 in the ubiquitin pathway and the close relationship 
between these PTMs [101]. A total of 70 TbNEDD8-conjugated and TbNEDD8-associated proteins 
were identified by mass spectrometry using ectopically expressed TbNEDD8, including all six of T. 
brucei Cullins that were further validated as genuine TbNEDD8 substrates [101]. However, due to 
issues with NEDD8 overexpression, substrates may have been erroneously modified using ubiquitin 
pathway machinery; therefore, these results should be considered with caution. Liao et al. also 
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analysed affinity-purified proteins from T. brucei expressing endogenous levels of tagged TbNEDD8, 
which revealed 16 proteins, including three Cullins, as putatively TbNEDD8-conjugated or 
TbNEDD8-associated, and might be a more accurate reflection of the natural substrates [101]. 
NEDD8-specific enzymatic machinery has also been investigated in Plasmodium falciparum. 
Bioinformatics analyses predicted orthologs of NEDD8, its cognate E1, E2, and E3s [19,20], as well as 
two Cullins. The enzymes mediating NEDD8 attachment in P. falciparum are essential [57], and the 
parasite is sensitive to the NEDD8 E1 inhibitor MLN4924 [51], indicating that P. falciparum requires a 
functional NEDDylation pathway. Surprisingly, orthologs of key deNEDDylases, NEDP1 and CSN, 
have not been found in this parasite. Moreover, an in silico analysis failed to identify the CSN 
subunits in apicomplexan parasites, alluding to either the complete loss of CSN function or the 
presence of a highly divergent complex in this group of organisms [102]. Remarkably, P. falciparum 
possesses two proteases that are capable of cleaving both ubiquitin and NEDD8 moieties, PfUCHL3 
[53,54] and PfUCH37 [52]. While UCHL3 enzymes from other organisms display a dual 
deNEDDylase/DUB activity, the ability of PfUCH37 to cleave NEDD8 is unusual. In particular, 
human UCH37 can only cleave ubiquitin, which marks an interesting distinction between the host 
and the parasite UCH37 enzymes and NEDD8 pathways. The molecular determinants guiding 
substrate specificity were identified, revealing that a single amino acid residue controls the ability of 
the enzyme to cleave NEDD8 [51]. Through targeted mutation, it was demonstrated that the 
deNEDDylase activity of PfUCH37 is dispensable for P. falciparum asexual blood stage survival, 
although its function in other life cycle stages remains to be determined. Since PfUCHL3 is unlikely 
to cleave NEDD8 from large substrates due to its structural features, deNEDDylation must either 
transpire via the action of an as of yet unidentified enzyme, or be entirely absent in the asexual stage 
of parasites. Promisingly, potentially novel deNEDDylases were identified as part of a functional 
proteomic screen utilising a P. falciparum-specific, activity-based probe designed to capture 
PfNEDD8-reactive enzymes, although their activity remains to be comprehensively validated [51].  
Curiously, CSN5 (also known as JAB1), the CSN catalytic subunit, was identified in E. histolytica 
as an interacting partner of the parasite-encoded macrophage migration inhibitory factor (MIF), a 
secreted proinflammatory cytokine implicated in invasion, pathogenesis, and immune evasion [103]. 
Direct interaction between EhJAB1 and EhMIF blocked the activity of the latter, as demonstrated by 
the inability of EhMIF to induce IL-8 production by human epithelial cells in the presence of EhJAB1. 
It was speculated that upon damage of E. histolytica cells, normally intracellular EhJAB1 may get 
released and act to suppress EhMIF-mediated inflammation, thereby creating a negative feedback 
mechanism. There is also a possibility of EhJAB1 interaction with human MIF, which could have an 
impact on the host inflammatory and immune responses [103].  
4. ATG8 and ATG12: Moonlighting Autophagy Machinery 
ATG8 and ATG12 have been extensively studied, mostly in the context of autophagy, an 
essential cellular process mediated by these Ubls. Autophagy involves engulfment of cytosolic 
components, which may include macromolecules, organelles, and pathogens, in double-membrane 
vesicles, referred to as autophagosomes, followed by fusion with lysosomes and subsequent 
degradation of the contents. This catabolic process eliminates excessive, defective, or toxic cytosolic 
components and recycles their degradation products as energy and metabolite sources, thereby 
maintaining cellular homeostasis and contributing to adaptive responses to stress, such as starvation 
[104]. 
ATG8 and ATG12 conjugation systems are functionally related and play a crucial role in 
autophagosome formation [105]. The covalent attachment of ATG12 to its protein substrate ATG5 is 
dependent on the E1 enzyme ATG7 and E2 enzyme ATG10, but does not involve an E3 ligase. The 
ATG12–ATG5 conjugate recruits ATG16L1 to form the ATG12–ATG5–ATG16L1 oligomeric complex 
that functions as an E3 ligase in the ATG8 conjugation pathway. Unlike most Ubls that modify protein 
substrates, ATG8 targets the head group of the phospholipid phosphatidylethanolamine (PE), which 
results in THE attachment of ATG8 to the cytosolic face of the autophagosomal membrane—a process 
that underlies autophagosome formation. The conjugation of ATG8 to PE, also referred to as 
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lipidation, is facilitated by ATG7 (E1), ATG3 (E2), and the aforementioned ATG12-ATG5-ATG16L1 
complex (E3), while ATG4 mediates ATG8 precursor processing and removal from substrates 
(delipidation) [105]. Remarkably, in mammals, both ATG8 and ATG4 genes are expanded to include 
multiple paralogs that display a certain degree of functional specialisation [18]. 
Bioinformatics analyses revealed that some core autophagy machinery, notably the ATG8 
conjugation system, is conserved in most parasitic protozoa [18,106,107]. However, there is ample 
evidence of substantial loss (particularly in G. lamblia), significant divergence (in apicomplexans), or 
elaboration (expansion of ATG8 family to include 25 paralogs in Leishmania [108]) of key proteins 
mediating autophagy, indicating that the mechanism and functions of autophagy may be different in 
these organisms [18,106,107]. Nevertheless, instances of autophagy-like processes, often supported 
by the presence of ATG8-positive structures, and their functional significance, have been reported for 
some parasitic protozoa. Examples include the encystation-associated autophagy-like process in 
Entamoeba [109], Acanthamoeba [110], and Naegleria [111], starvation-induced autophagy in T. vaginalis 
[112,113] and T. cruzi [114], glycosome turnover and damaged organelle removal by autophagy in 
Leishmania [115], and autophagy triggered by endoplasmic reticulum (ER) stress in T. gondii [116]. 
Notably, it was demonstrated that in apicomplexan parasites P. falciparum and T. gondii ATG8 
takes on an autophagy-independent role associated with the apicoplast. The apicoplast is a non-
photosynthetic plastid that is characteristic of most apicomplexans and is a product of secondary 
endosymbiosis between an apicomplexan ancestor and a chloroplast-containing red alga. Following 
significant reduction, the apicoplast emerged as the stroma and circular genome of the red alga 
endosymbiont’s plastid surrounded by four membranes. Although the role of the apicoplast appears 
to diminish in a number of apicomplexans, resulting in its devolution, this organelle remains essential 
for survival of the parasites with complex life cycles that involve switching between different hosts 
and tissue types, such as Plasmodium and Toxoplasma [117,118].  
It was observed that ATG8 localises to the apicoplast, in all likelihood as the ATG8-PE conjugate, 
in P. falciparum [119–121] and T. gondii [122,123]. Upon TgATG8 depletion, T. gondii displayed growth 
cessation and defective segregation of the apicoplast into progeny, leading to loss of the organelle 
and prompting a link between this Ubl and apicoplast maintenance [122]. The crucial role of PfATG8 
was demonstrated by the lethality of PfATG8 knockout to blood stage P. falciparum. The ensuing 
parasite death is due to apicoplast loss, likely brought on by inability to segregate the apicoplast 
during replication [124]. It was also reported that PfATG7 depletion inhibits parasite proliferation 
[124,125], and TgATG4 [123] is required for parasite growth and apicoplast maintenance, further 
supporting the essential role of the ATG8 pathway towards ensuring the proper function of this 
unusual organelle. The link between the ATG8 pathway and crucial parasite-specific process of 
apicoplast biogenesis has opened new avenues in anti-apicomplexan drug design. Upon structural 
analysis of the interaction between PfATG8 and its cognate E2 PfATG3 in P. falciparum, the structural 
loop that mediates the interaction was discovered in PfATG8, but not in its human counterpart [126]. 
This distinguishing feature enabled the development of parasite-specific inhibitors that selectively 
block PfATG8-PfATG3 interaction in P. falciparum and inhibit parasite growth [126–129]. 
Strikingly, the ATG12 pathway in apicomplexan parasites exhibits a significant divergence from 
the conventional one. The absence of ATG10 and the C-terminal glycine of ATG12 in these parasites 
pointed to the lack of functional ability to perform covalent attachment of ATG12 to ATG5. Instead, 
it was demonstrated that ATG12 and ATG5 orthologs from P. falciparum and T. gondii form a complex 
via non-covalent interaction, while retaining the ability to mediate ATG8 lipidation. This alteration 
in the ATG12 pathway in apicomplexans may be an example of reductive evolution leading to 
simplification of an energy-demanding Ubl pathway with a very limited substrate range to a non-
covalent interaction [130]. 
5. URM1: The Old-Timer 
URM1 is the ancestral Ubl that is most closely related to MoaD and ThiS, the prokaryotic 
antecedents of ubiquitin and Ubls. Through a mechanism reminiscent of the activity of these bacterial 
sulfur carriers, URM1 thiolates some eukaryotic tRNAs, thereby modulating their stability and 
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functional properties [18,131]. Furthermore, URM1 functions as a protein PTM by modifying lysine 
residues of its substrates [18,131], mediated by a single E1-like enzyme Uba4 containing an additional 
rhodanese-like domain that confers sulfurtransferase activity [132]. Strikingly, no URM1-specific E2, 
E3, or deURMylase enzymes have been identified so far. It was discovered that URMylation is 
significantly induced by oxidative stress and targets a limited set of specific protein substrates. Based 
on its structural and functional features, URM1 may be considered an evolutionary intermediate that 
combines the roles of prokaryotic sulfur carriers with those of eukaryotic post-translational modifiers 
[18,131]. 
The NMR structure of Trypanosoma brucei URM1 revealed a conserved MoaD/ThiS-related fold 
and the close structural similarity to bacterial MoaD and S. cerevisiae URM1 [133]. Furthermore, 
URM1 and Uba4 have been bioinformatically predicted and functionally characterised in Leishmania 
donovani [134]. L. donovani that expressed a non-conjugatable form of LdURM1 presented with 
reduced growth and defective cell division, indicating that this Ubl may be involved in the regulation 
of cell division. Twenty six proteins that may represent URMylation substrates in this organism were 
identified by mass spectrometry following immunoprecipitation with an anti-LdURM1 antibody. The 
presence of LdRab5 and LdRab GTPase among these proteins, as well as the enrichment of LdURM1 
in proximity of the flagellar pocket, prompted a speculation that LdURM1 may modulate endosome-
mediated haemoglobin uptake through a specific receptor located in the flagellar pocket of L. donovani 
[134]. Although an URM1 ortholog exists in all other parasitic protozoans, its function has not been 
explored in these organisms to date. 
6. UFM1: Expect the Unexpected 
A relatively new addition to the Ubl family, UFM1, is conserved in multicellular organisms, but 
is absent in yeast. The attachment of UFM1 to lysines of its protein substrates is mediated by the E1 
enzyme Uba5, the E2 enzyme Ufc1, and the E3 enzyme Ufl1. The UFM1-specific proteases, Ufsp1 and 
Ufsp2, function both as UFM precursor processing enzymes and deUFMylases. Notably, the UFM1 
pathway is closely linked to ER function, as demonstrated by ER localisation of the transmembrane 
E3 Ufl1 and the upregulation of the pathway components by ER stress. While the pool of reported 
UFM1-modified proteins is small, this Ubl was shown to be crucial for the ER stress response, cell 
development and differentiation, and tissue homeostasis [135,136]. 
Given its association with multicellular organisms, the discovery of a UFM1 ortholog, as well as 
active UFMylation enzymatic machinery, in Leishmania donovani [137,138] was surprising. 
Unexpectedly, it was found that LdUFM1 and its cognate enzymes are associated with the 
mitochondria, as evidenced by their cellular localisation and the detection of two mitochondrial 
proteins, the 40S ribosomal protein SA and the mitochondrial trifunctional protein (MTP) α-subunit, 
in L. donovani lysate fractions enriched for LdUFM1 conjugates [137]. LdMTP was subsequently 
confirmed as a genuine in vivo UFMylation substrate in this parasite [139]. The role of LdUFM1 in 
the mitochondrial processes was further underscored by the disruption of the essential MTP-
mediated β-oxidation of fatty acids in L. donovani UFM1 null mutant strain (Ufm1-/-). Lack of LdUFM1 
in this strain led to the inhibition of L. donovani amastigote growth in vitro and ex vivo in human 
macrophages, suggesting that LdUFM1 is required for cell division and pathogenesis [139]. 
Furthermore, the L. donovani strain that lacks Ufsp, the LdUFM1-specific protease, displayed similarly 
compromised growth in vitro and ex vivo, as well as reduced virulence in mouse infections [138]. 
This finding suggests that the Ufsp knockout strain of L. donovani is an attractive candidate to be 
tested as a live attenuated vaccine. Moreover, it was demonstrated that the activity of LdUfsp can be 
inhibited by the anti-leishmanial drug amphotericin B, thereby supporting the validity of this enzyme 
as a chemotherapy target [138]. UFM1 has now been bioinformatically predicted to function in 
Trypamosoma, Giardia, and Toxoplasma, although its biological function has not been studied in these 
organisms to date. 
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7. PUBL: The New Kid on the Block? 
An extreme example of Ubl divergence in protozoans is plastid ubiquitin-like protein (PUBL), a 
novel, apicoplast-targeted modifier with high homology to ubiquitin that was discovered in 
Toxoplasma gondii [140]. Putative homologs of PUBL were identified in multiple apicomplexan 
parasites, with the exception of Plasmodium. It was demonstrated that PUBL is essential for T. gondii 
growth and protein import into the apicoplast, pointing to a potential link with the apicoplast-specific 
endoplasmic reticulum-associated protein degradation (ERAD) complex, known to mediate import 
into this organelle [140]. Unlike the conventional ERAD systems that function as the ER quality 
control mechanisms of the secretory pathway and target misfolded proteins for degradation, the algal 
endosymbiont-derived apicoplast ERAD complex is repurposed for protein import into the organelle. 
In addition to its divergence, the functional apicoplast ERAD system is essential for T. gondii survival 
[141], and PUBL conjugation machinery may thus hold potential as novel targets for anti-
apicomplexan drug development. 
8. Conclusions and Future Perspectives 
Parasitic protozoa employ a variety of Ubls that are structurally conserved across eukaryotes as 
post-translational modifiers. SUMO, NEDD8, and URM1 have been identified in all major lineages 
of these parasites, while ATG8, ATG12, and UFM1 are not uniformly present. For some Ubls, 
functional conservation is observed in mammalian cells and model organisms, as well as in protozoan 
parasites, as exemplified by SUMO and ATG8 that regulate stress responses and autophagy, 
respectively. However, these highly specialised unicellular parasites also utilise Ubls in unorthodox 
ways to facilitate unique processes that underpin their unusual physiology (Figure 2). The diversity 
of novel regulatory functions performed by Ubls reflects the diversity of cellular organisations and 
lifestyles in this polyphyletic group of parasites. Remarkably, multiple Ubls control the formation 
and function of parasite-specific organelles and life forms. In particular, SUMO mediates adhesive 
disc formation and encystation in G. lamblia, ATG8 is essential for apicoplast maintenance in 
apicomplexan parasites, while both NEDD8 and SUMO are required for normal flagellar function in 
trypanosomes. Furthermore, some Ubls in parasitic protozoa perform unexpected functions that are 
not related, or even contrary, to the roles of their counterparts in other organisms. Chromatin 
SUMOylation is linked to transcriptional activation of VSG in T. brucei, even though in other 
organisms this modification mainly leads to transcriptional repression. UFM1 regulates 
mitochondrial processes in L. donovani, in contrast to its conventional role in ER function. In addition 
to the functional divergence of Ubls, parasitic protozoa demonstrate distinctive features in Ubl 
enzymatic pathways, such as the replacement of ATG12 conjugation to its ATG5 substrate with a 
non-covalent interaction, and lack of CSN in apicomplexans. 
Since Ubls are essential in facilitating a range of parasite-specific processes, enzymes mediating 
the Ubl pathways may hold therapeutic potential as targets for development of drugs against diseases 
caused by parasitic protozoa. Notably, Ubls have been implicated in the mode of action of multiple 
existing drugs that show anti-parasite activity, including benzoxaborole AN13762, monensin, and 
the isocryptolepine derivative ICL-M. Furthermore, the presence of distinctive structural features on 
the interacting surfaces of cognate enzymes allows specific targeting of parasitic Ubl pathways, while 
leaving host Ubl pathways unaffected. Such selective targeting is very promising from a drug design 
perspective and has been achieved for SUMO and ATG8 pathways through inhibition of Uba2–Uba9 
and ATG8–ATG3 interactions in P. falciparum. Furthermore, given the evolutionary conservation and 
necessity of these pathways to survival in all eukaryotes, it would follow that these Ubls are essential 
across the entire life cycle of parasitic protozoans. As such, developing therapeutics that target 
specific components of Ubl machinery may yield inhibitors that prove effective against multiple 
stages of parasite development, something that has been a challenge with currently available drugs.  
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Figure 2. Cellular processes regulated by ubiquitin-like modifiers (Ubls) in protozoan parasites. 
From the data on Ubls in parasitic protozoa that have accumulated to date, we can glean the 
significance of these underexplored PTMs for the cellular physiology of parasites and potential 
applicability of Ubl pathways for drug development. Although these pathways are evolutionarily 
conserved, it is becoming increasingly evident that Ubls regulate distinct cellular processes in 
different species of parasitic protozoa and that their cognate enzymatic machinery displays unique 
features. This functional and structural divergence necessitates further research into these modifiers 
in a variety of parasitic protozoa, with the aim of improving our understanding of the regulatory 
functions of Ubls across the whole spectrum of these pathogenic organisms and harnessing their 
essential and unique roles for novel drug design. 
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